The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

SureCN2773923     (2R)-N-[(2S)-3-hydroxy-4-(2- methylpropyl...

Synonyms: NSC 670881, AC1L1U39, AC1Q5L33, SC 52151, 143224-34-4, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of SC-52151

 

High impact information on SC-52151

 

Chemical compound and disease context of SC-52151

 

Biological context of SC-52151

 

Anatomical context of SC-52151

 

Associations of SC-52151 with other chemical compounds

 

Gene context of SC-52151

  • The combination of DEC with compound E demonstrated marginal enhancement in adulticidal efficacy, however, the embryostatic effect of the duo was significantly higher than that exerted by the individual agents [15].
 

Analytical, diagnostic and therapeutic context of SC-52151

  • In contrast, SC-52151-resistant variants selected from the monocytotropic strain SF162 had multiple substitutions in the protease gene (I11V, M461, F53L, A71V, and N88D), and the N88D mutation, re-created by oligonucleotide-mediated site-directed mutagenesis in HXB2, did not confer resistance to SC-52151 [7].
  • 1. SC-52151, an HIV protease inhibitor, is mainly metabolized by CYP3A4 and is poorly bioavailable after oral administration [8].

References

  1. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Bryant, M., Getman, D., Smidt, M., Marr, J., Clare, M., Dillard, R., Lansky, D., DeCrescenzo, G., Heintz, R., Houseman, K. Antimicrob. Agents Chemother. (1995) [Pubmed]
  2. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line. Furuta, M., Nozawa, K., Takemura, M., Izuta, S., Murate, T., Tsuchiya, M., Yoshida, K., Taka, N., Nimura, Y., Yoshida, S. Int. J. Cancer (2003) [Pubmed]
  3. The effects of the new antiarrhythmic E 047/1 on postoperative ischemia-induced arrhythmias in dogs. Kulier, A.H., Novalija, E., Hogan, Q., Vicenzi, M.N., Woehlck, H.J., Bajic, J., Atlee, J.L., Bosnjak, Z.J. Anesth. Analg. (1999) [Pubmed]
  4. The anthelmintic effects of a new compound "E" (Friedheim) on Onchocerca gutturosa in the cow--a possible tertiary screening system for drug action against O. volvulus in man. Denham, D.A., Mellor, P. J. Helminthol. (1976) [Pubmed]
  5. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Coezy, E., Borgna, J.L., Rochefort, H. Cancer Res. (1982) [Pubmed]
  6. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. Lazdins, J.K., Mestan, J., Goutte, G., Walker, M.R., Bold, G., Capraro, H.G., Klimkait, T. J. Infect. Dis. (1997) [Pubmed]
  7. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Smidt, M.L., Potts, K.E., Tucker, S.P., Blystone, L., Stiebel, T.R., Stallings, W.C., McDonald, J.J., Pillay, D., Richman, D.D., Bryant, M.L. Antimicrob. Agents Chemother. (1997) [Pubmed]
  8. Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Yuan, J.H., Stolzenbach, J.C., Salamon, C.M., Snook, S.S., Schoenhard, G.L. Xenobiotica (1997) [Pubmed]
  9. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. Fischl, M.A., Richman, D.D., Flexner, C., Para, M.F., Haubrich, R., Karim, A., Yeramian, P., Holden-Wiltse, J., Meehan, P.M. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1997) [Pubmed]
  10. Initiating, promoting and carcinogenic activities of three naphthofurans in a mouse skin long-term study. Lasne, C., Venegas, W., Royer, R., Chouroulinkov, I. Jpn. J. Cancer Res. (1987) [Pubmed]
  11. Contribution of presenilin/gamma-secretase to calsenilin-mediated apoptosis. Jo, D.G., Chang, J.W., Hong, H.S., Mook-Jung, I., Jung, Y.K. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  12. Potent inhibitory effects of N-aryl S-alkylthiocarbamate derivatives on the dopa oxidase activity of mushroom tyrosinase. Lee, K.H., Koketsu, M., Choi, S.Y., Lee, K.J., Lee, P., Ishihara, H., Kim, S.Y. Chem. Pharm. Bull. (2005) [Pubmed]
  13. Determination of protein binding by in vitro charcoal adsorption. Yuan, J., Yang, D.C., Birkmeier, J., Stolzenbach, J. Journal of pharmacokinetics and biopharmaceutics. (1995) [Pubmed]
  14. An historical review of rheumatoid arthritis treatment: 1948 to 1952. Karsh, J., Hetenyi, G. Semin. Arthritis Rheum. (1997) [Pubmed]
  15. Search for new prototypes for the chemotherapy of filariasis: a chemotherapeutic and biochemical approach. Bajpai, P., Verma, S.K., Katiyar, D., Tewari, N., Tripathi, R.P., Bansal, I., Saxena, J.K., Misra-Bhattacharya, S. Parasitol. Res. (2005) [Pubmed]
 
WikiGenes - Universities